<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04488926</url>
  </required_header>
  <id_info>
    <org_study_id>MPS-FM</org_study_id>
    <nct_id>NCT04488926</nct_id>
  </id_info>
  <brief_title>Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients</brief_title>
  <official_title>Efficacy and Tolerability of Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients: A Double-blind, Randomized, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epitech Group SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Epitech Group SpA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The onset of chronic Fibromyalgia symptomatology is due to central alterations, together with
      peripheral neuroimmune modifications. Using positron emission tomography (PET), it has been
      observed for the first time that fibromyalgia patients have a high activation of microglial
      cells compared to normal subjects. Experimental evidence in neuroinflammation models in vitro
      and in vivo have demonstrated the anti-inflammatory and neuroprotective effect of
      Palmitoylethanolamide (PEA), effects confirmed by observational clinical investigations
      conducted in patients with fibromyalgia in which micronized and ultra-micronized
      Palmitoylethanolamide (mPEA and umPEA) reduced the intensity of pain improving the quality of
      life. The aim of this study is to investigate the efficacy and tolerability of PEA-m + PEA-um
      administered as an add-on therapy with a double-blind, randomized, placebo-controlled
      clinical investigation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibromyalgia symptoms assessed by Fibromyalgia Impact Questionnaire Revised</measure>
    <time_frame>90 days</time_frame>
    <description>Change of Fibromyalgia symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity assessed by Visual Analogue Scale</measure>
    <time_frame>90 days</time_frame>
    <description>Change of Visual Analogue Scale every 30 days (0: no pain - 100 mm: maximum pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health assessed by Short form-12 Health Survey</measure>
    <time_frame>90 days</time_frame>
    <description>Change in Health at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Disorders assessed by Pittsburgh Sleep Quality Index</measure>
    <time_frame>90 days</time_frame>
    <description>Change in sleep disorders at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Drugs consumption assessed by a daily diary</measure>
    <time_frame>90 days</time_frame>
    <description>Change in rescue drugs consumption during the entire period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>90 days</time_frame>
    <description>Monitoring of adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test</measure>
    <time_frame>90 days</time_frame>
    <description>Clinically significant changes in blood test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normast® MPS (mPEA and umPEA 300mg + 600mg) microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules</intervention_name>
    <description>Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Normast® MPS microgranules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo microgranules 1800mg</intervention_name>
    <description>Placebo was prepared to be indistinguishable from color and flavor from the Product</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>(antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue Drug</intervention_name>
    <description>Use as needed allowed</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Paracetamol or Fans</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Fibromyalgia according to the criteria of the American College of
             Rheumatology 2016 (symptoms for at least 3 months, Widespread Pain Index (WPI) ≥ 7 and
             Symptom Severity (SS) ≥ 5 or WPI 4-6 and SS ≥ 9)

          -  Pain intensity assessed on the Visual Analogue Scale (VAS) ≥ 40

          -  PEA-naive patients

          -  Patients who agree to sign informed consent

        Exclusion Criteria:

          -  Values of WPI &lt;7 and SS &lt;5

          -  Pain intensity assessed on the Visual Analogue Scale (VAS) &lt;40

          -  Patients who have already taken PEA in the past

          -  Allergic or hypersensitive subjects to the product and / or one or more of its
             excipients

          -  Patients who refuse to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrico Polati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria Integrata di Verona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Epitech Group SpA Clinical Research</last_name>
    <phone>+39 049 8016784</phone>
    <email>info@epitech.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anestesia e Rianimazione B - Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Polati, MD</last_name>
    </contact>
    <investigator>
      <last_name>Prof. Enrico Polati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prof. Vittorio Schweiger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30827269/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Schweiger V, Martini A, Bellamoli P, Donadello K, Schievano C, Balzo GD, Sarzi-Puttini P, Parolini M, Polati E. Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. CNS Neurol Disord Drug Targets. 2019;18(4):326-333. doi: 10.2174/1871527318666190227205359.</citation>
    <PMID>30827269</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palmidrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

